{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:17:01Z","timestamp":1792556221213,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Percutaneous thermal ablation combined with in situ granulocyte-macrophage colony-stimulating factor cytokine therapy was technically feasible and well tolerated. No significant clinical or immunologic responses were seen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Melanoma tumor-derived heat-shock proteins (HSPs) and HSP-peptide complexes can elicit protective antitumor responses. The granulocyte-macrophage colony-stimulating factor (GM-CSF) chemokine can also promote uptake and processing by professional antigen presenting cells (APCs). On this basis, we designed a pilot study of percutaneous thermal ablation as a means to induce heat-shock protein vaccination plus GM-CSF to determine safety and preliminary antitumor activity of this combination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>This study was designed to assess overall safety of percutaneous ablation combined with GM-CSF for unresectable, metastatic melanoma including uveal and mucosal types. All patients received heat-shock therapy (42\u00b0C for 30 minutes), then received one of three treatments: (a) intralesional GM-CSF (500 mcg standard dose); (b) radiofrequency ablation (RFA)\u2009+\u2009GM-CSF; or (c) cryoablation plus GM-CSF. The primary endpoint of the study was the induction of endogenous HSP70 and melanoma-specific cytotoxic T lymphocytes (CTL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nine patients (three per study arm) were enrolled. No dose-limiting toxicity was observed as specified per protocol. All patients developed progressive disease and went on to receive alternative therapy. Median overall survival (OS) was 8.2 months (95% confidence interval [CI] 2\u201317.2). The study was not powered to detect a difference in clinical outcome among treatment groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Percutaneous thermal ablation plus GM-CSF was well tolerated, technically feasible, and demonstrated an acceptable adverse event profile comparable to conventional RFA and cryoablation. While HSP70 was induced following therapy, the degree of HSP70 elevation was not associated with clinical outcome or induced CTL responses. While percutaneous thermal ablation plus GM-CSF combinations including checkpoint inhibitors could be considered in future studies, the use of GM-CSF remains experimental and for use in the context of clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0060","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T01:00:29Z","timestamp":1499302829000},"page":"1026-e93","source":"Crossref","is-referenced-by-count":17,"title":["Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma"],"prefix":"10.1093","volume":"22","author":[{"given":"Evidio","family":"Domingo-Musibay","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Heun","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Dean Clinic, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy K.","family":"Nevala","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Callstrom","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Atwell","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Galanis","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Erickson","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"2021122508215755600_onco12192-bib-0001","first-page":"193","article-title":"Prognostic factors in 1,521 melanoma patients with distant metastases","volume":"181","author":"Barth","year":"1995","journal-title":"J Am Coll Surg"},{"key":"2021122508215755600_onco12192-bib-0002","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"2021122508215755600_onco12192-bib-0003","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coi.2015.12.006","article-title":"Melanoma: The intersection of molecular targeted therapy and immune checkpoint inhibition","volume":"39","author":"Lau","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"2021122508215755600_onco12192-bib-0004","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1158\/0008-5472.CAN-15-2644","article-title":"In situ tumor vaccination by combining local radiation and tumor-specific antibody or immunocytokine treatments","volume":"76","author":"Morris","year":"2016","journal-title":"Cancer Res"},{"key":"2021122508215755600_onco12192-bib-0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2021122508215755600_onco12192-bib-0006","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"2021122508215755600_onco12192-bib-0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122508215755600_onco12192-bib-0008","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"key":"2021122508215755600_onco12192-bib-0009","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/jso.23929","article-title":"Liver resection and ablation for metastatic melanoma: A single center experience","volume":"111","author":"Doussot","year":"2015","journal-title":"J Surg Oncol"},{"key":"2021122508215755600_onco12192-bib-0010","doi-asserted-by":"crossref","first-page":"31688","DOI":"10.1074\/jbc.M704129200","article-title":"Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling","volume":"282","author":"Bendz","year":"2007","journal-title":"J Biol Chem"},{"key":"2021122508215755600_onco12192-bib-0011","first-page":"222","article-title":"Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells","volume":"61","author":"Castelli","year":"2001","journal-title":"Cancer Res"},{"key":"2021122508215755600_onco12192-bib-0012","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2021122508215755600_onco12192-bib-0013","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature19947","article-title":"Proteome complexity and the forces that drive proteome imbalance","volume":"537","author":"Harper","year":"2016","journal-title":"Nature"},{"key":"2021122508215755600_onco12192-bib-0014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12192-008-0068-7","article-title":"Guidelines for the nomenclature of the human heat shock proteins","volume":"14","author":"Kampinga","year":"2009","journal-title":"Cell Stress Chaperones"},{"key":"2021122508215755600_onco12192-bib-0015","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/carcin\/bgt111","article-title":"The HSP70 family and cancer","volume":"34","author":"Murphy","year":"2013","journal-title":"Carcinogenesis"},{"key":"2021122508215755600_onco12192-bib-0016","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1158\/0008-5472.CAN-15-2137","article-title":"HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors","volume":"76","author":"Budina-Kolomets","year":"2016","journal-title":"Cancer Res"},{"key":"2021122508215755600_onco12192-bib-0017","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1074-7613(02)00388-6","article-title":"Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation","volume":"17","author":"Delneste","year":"2002","journal-title":"Immunity"},{"key":"2021122508215755600_onco12192-bib-0018","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/j.febslet.2005.02.046","article-title":"Extracellular HSP70 binding to surface receptors present on antigen presenting cells and endothelial\/epithelial cells","volume":"579","author":"Theriault","year":"2005","journal-title":"FEBS Lett"},{"key":"2021122508215755600_onco12192-bib-0019","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1074-7613(01)00111-X","article-title":"CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin","volume":"14","author":"Basu","year":"2001","journal-title":"Immunity"},{"key":"2021122508215755600_onco12192-bib-0020","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.4049\/jimmunol.177.12.8604","article-title":"Role of scavenger receptors in the binding and internalization of heat shock protein 70","volume":"177","author":"Theriault","year":"2006","journal-title":"J Immunol"},{"key":"2021122508215755600_onco12192-bib-0021","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fimmu.2016.00171","article-title":"Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer","volume":"7","author":"Shevtsov","year":"2016","journal-title":"Front Immunol"},{"key":"2021122508215755600_onco12192-bib-0022","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2008-06-162727","article-title":"Heat shock protein 70 (HSP70) induces cytotoxicity of T-helper cells","volume":"113","author":"Figueiredo","year":"2009","journal-title":"Blood"},{"key":"2021122508215755600_onco12192-bib-0023","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1158\/2326-6066.CIR-14-0165","article-title":"Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: Recruitment and activation of BDCA3\/CD141(+) dendritic cells and enhanced cross-presentation","volume":"3","author":"Sluijter","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2021122508215755600_onco12192-bib-0024","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/ijc.21795","article-title":"HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma","volume":"118","author":"Geng","year":"2006","journal-title":"Int J Cancer"},{"key":"2021122508215755600_onco12192-bib-0025","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1586\/erv.11.124","article-title":"Heat shock proteins and cancer vaccines: Developments in the past decade and chaperoning in the decade to come","volume":"10","author":"Murshid","year":"2011","journal-title":"Expert Rev Vaccines"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0060","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/9\/1026\/41916351\/oncolo_22_9_1026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/9\/1026\/41916351\/oncolo_22_9_1026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:22:52Z","timestamp":1640420572000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/9\/1026\/6444568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,7,5]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0060","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9,1]]},"published":{"date-parts":[[2017,7,5]]}}}